Pharmafile Logo

Akorn

- PMLiVE

Data integrity scuppers Fresenius deal with Akorn

However Fresenius could be liable to pay $129m in termination fees

- PMLiVE

Fresenius says Akorn investigation could affect takeover

External ‘experts’ are investigating alleged breaches of data integrity requirements

- PMLiVE

Fresenius Kabi buys Akorn and Merck’s biosimilar businesses

German-based firm predicts savings after it unites the two biopharma companies

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links